Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $103,566.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 12,300 shares of the business’s stock in a transaction on Monday, March 24th. The stock was bought at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This trade represents a 58.57 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Stock Performance

Shares of IMNM opened at $6.95 on Wednesday. The firm’s 50-day simple moving average is $9.67 and its 200 day simple moving average is $11.44. The firm has a market cap of $604.31 million, a P/E ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a 52 week low of $6.94 and a 52 week high of $26.70.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

IMNM has been the topic of several analyst reports. Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Guggenheim cut their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $25.50.

Institutional Investors Weigh In On Immunome

Several institutional investors have recently made changes to their positions in IMNM. Wellington Management Group LLP increased its stake in Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after purchasing an additional 2,005 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Immunome by 32.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock worth $618,000 after purchasing an additional 14,328 shares during the period. Woodline Partners LP raised its stake in Immunome by 6.1% in the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock valued at $10,417,000 after purchasing an additional 56,533 shares in the last quarter. Finally, Two Sigma Advisers LP bought a new stake in Immunome during the fourth quarter worth about $512,000. 44.58% of the stock is currently owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.